stockrow
Saturday 7 November 2026
Export JUNS’s income statement to Excel — free account
Jupiter Neurosciences, Inc.
JUNS Healthcare Biotechnology
Jupiter Neurosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $21,800.00, down 90.7% from fiscal 2022.
- EPS
- +22.5%
- Free cash flow
- −177.1%
Quarter to June 2026, against a year earlier
2.27
0.14
+6.57%
Follow JUNS
Alert me
| Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|
P/E ratio |
0.00 | — | — | 0.00 |
P/S ratio |
0.00 | — | — | 0.00 |
Altman Z-Score |
— | — | — | (11.70) |
P/FCF ratio |
0.00 | — | — | 0.00 |
Altman Z″-Score (non-manufacturers) |
(558.55) | — | — | (34.36) |
P/Operating CF |
(3,994.75) | — | — | (14.88) |
P/B ratio |
0.00 | — | — | 0.00 |
Price to Tangible BV |
0.00 | — | — | 0.00 |
EV/Sales |
0.00 | — | — | 0.00 |
EV/EBITDA |
0.00 | — | — | 0.00 |
EV/Operating CF |
(452.44) | — | — | (5.83) |
EV/FCF |
(452.44) | — | — | (5.83) |
Quick Ratio |
0.01 | 0.00 | 1.88 | 0.51 |
Current Ratio |
0.01 | 0.01 | 2.31 | 0.65 |
Net Debt/EBITDA |
0.02 | (0.02) | 1.24 | 0.43 |
Debt/Assets |
0.00% | 71.80% | 0.00% | 0.00% |
Debt/Equity |
0.00 | (0.02) | 0.00 | 0.00 |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
0.25 | 0.10 | 1.60 | 0.63 |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | — |
Interest Coverage |
(4.63) | (17.70) | (12.44) | (134.98) |
| 0.00% | 73.91% | 299.45% | (738.85%) | |
| 0.00% | (2,488.27%) | (76.83%) | (146.94%) | |
ROIC |
0.00% | 0.00% | (480.02%) | 0.00% |
Return on Tangible Assets |
68.94% | 83.29% | (92.37%) | 336.26% |
Average Days of Receivables |
0.00 | — | — | 43.53 |
Research and Development Expense of Revenue |
404.11% | 0.00% | 0.00% | 9,571.56% |
Selling, General and Administrative Expense of Revenue |
1,167.12% | 0.00% | 0.00% | 31,374.77% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
323.53% | 0.00% | 0.00% | 11,094.04% |
Graham Net Nets |
(0.03) | — | — | (0.07) |
Graham Number |
0.00 | — | — | 41.83 |
Earnings Yield |
(1.82%) | — | — | (25.55%) |
Free Cash Flow Yield |
(0.22%) | — | — | (15.36%) |
Revenue per Share |
0.69 | 0.00 | 0.00 | 0.05 |
Operating CF per Share |
(3.69) | (1.37) | (10.22) | (11.75) |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 |
Free Cash Flow per Share |
(3.69) | (1.37) | (10.22) | (11.75) |
Cash per Share |
0.19 | 0.08 | 9.85 | 8.23 |
Shareholders Equity per Share |
(21.11) | (16.52) | 10.90 | (3.98) |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
(21.11) | (16.52) | 10.90 | (3.98) |
Free Cash Flow |
(1.25) | (0.48) | (3.91) | (5.41) |
Working Capital |
(7.19) | (5.74) | 2.64 | (2.57) |
Net Current Asset Value |
(7.31) | (5.92) | 2.62 | (2.57) |
EV/EBIT |
0.00 | — | — | 0.00 |
Capex to Sales |
0.00 | — | — | 0.00 |
Price to Operating Income |
0.00 | — | — | 0.00 |
| Other line items | ||||
Depreciation/Fixed assets |
0.00 | 0.00 | 0.00 | — |
Cash ROIC |
17.63% | 8.49% | (49.25%) | (276.58%) |
Accounts Receivable Turnover |
0.00 | — | — | 0.00 |
Accounts Payable Turnover |
— | 0.00 | 0.00 | 0.01 |
Inventory Turnover |
— | — | — | 0.00 |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 55,497.38 |
Days of Inventory on Hand |
— | — | — | 13,887.38 |
Average Payables |
— | 0.54 | 0.47 | 0.52 |
Average Assets |
— | 0.19 | 3.18 | 5.88 |
Average Common Equity |
— | (6.47) | (0.81) | 1.17 |
Columns are period end dates